Follow us on:

Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss a distribution agreement with Medusa 19 for its rapid antigen test direct to consumer. Alastair talks us through this latest news, provides an update on the development of the tests and provides details around the potential Affimer treatment for COVID 19.

Avacta Group’s Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

Find more news, interviews, share price & company profile here for:Avacta Group Plc

Share this interview

Other Interviews

More News

Avacta Group notice of results and investor presentation April 13, 2021
Avacta Group Win Diagnostic Licensing Deal with Biokit March 9, 2021
Avacta Group MHRA approves Clinical Trial & Excellent data from Lateral Flow Rapid Antigen Test February 24, 2021
Avacta Group Phase I Clinical Trial Approval by MHRA for AVA6000 February 18, 2021
Avacta Group SARS-CoV-2 lateral flow antigen test results show excellent performance February 16, 2021
Avacta Group announce commercial partnership with Mologi to accelerate CE marking of rapid antigen test February 8, 2021
Avacta Group secures AffyXell $7.3 Million Series A venture funding February 1, 2021
Avacta Group announce agreement with POINT Biopharma Inc. for pre|CISION™ technology January 7, 2021
Avacta Group submits application for AVA6000 Pro-doxorubixin trial December 23, 2020
Avacta Group significant progress made on SARS-CoV-2 rapid antigen test November 23, 2020

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.